BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 180 filers reported holding BRIDGEBIO PHARMA INC in Q4 2022. The put-call ratio across all filers is 0.41 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $672,513 | +54.7% | 25,503 | +0.9% | 0.00% | +100.0% |
| Q2 2023 | $434,816 | +14.2% | 25,280 | +10.1% | 0.00% | 0.0% |
| Q1 2023 | $380,610 | +92.2% | 22,956 | -11.7% | 0.00% | 0.0% |
| Q4 2022 | $198,013 | -17.1% | 25,986 | +8.3% | 0.00% | 0.0% |
| Q3 2022 | $239,000 | +5.3% | 24,001 | -4.1% | 0.00% | 0.0% |
| Q2 2022 | $227,000 | -40.4% | 25,020 | -33.5% | 0.00% | 0.0% |
| Q1 2022 | $381,000 | -51.0% | 37,637 | -19.2% | 0.00% | -50.0% |
| Q4 2021 | $778,000 | -65.7% | 46,605 | -3.7% | 0.00% | -66.7% |
| Q3 2021 | $2,267,000 | -32.1% | 48,371 | -11.6% | 0.01% | -40.0% |
| Q2 2021 | $3,337,000 | +18.0% | 54,744 | +19.2% | 0.01% | +11.1% |
| Q1 2021 | $2,829,000 | +13.5% | 45,922 | +31.0% | 0.01% | 0.0% |
| Q4 2020 | $2,492,000 | +131.8% | 35,050 | +22.4% | 0.01% | +80.0% |
| Q3 2020 | $1,075,000 | +12.6% | 28,646 | -2.2% | 0.01% | 0.0% |
| Q2 2020 | $955,000 | +53.8% | 29,292 | +36.9% | 0.01% | +25.0% |
| Q1 2020 | $621,000 | -40.5% | 21,398 | -28.2% | 0.00% | -20.0% |
| Q4 2019 | $1,044,000 | – | 29,786 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 3,835,722 | $103,449,000 | 44.18% |
| Kohlberg Kravis Roberts & Co. L.P. | 36,900,661 | $995,211,000 | 12.26% |
| SC US (TTGP), LTD. | 2,544,738 | $68,632,000 | 4.69% |
| Cormorant Asset Management, LP | 2,780,885 | $75,000,000 | 4.31% |
| Perceptive Advisors | 6,706,268 | $180,868,000 | 4.15% |
| VIKING GLOBAL INVESTORS LP | 26,620,991 | $717,968,000 | 3.22% |
| Hillhouse Capital Management | 2,035,790 | $54,905,000 | 1.75% |
| Alpine Group USVI, LLC | 20,000 | $539,000 | 1.70% |
| HHLR ADVISORS, LTD. | 2,352,900 | $63,458,000 | 1.42% |
| SCGE MANAGEMENT, L.P. | 588,235 | $15,865,000 | 0.79% |